289 related articles for article (PubMed ID: 26436722)
21. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
Lu HY; Zhuang LW; Yu YY; Si CW; Li J
Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
[TBL] [Abstract][Full Text] [Related]
22. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
[TBL] [Abstract][Full Text] [Related]
23. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
Lampertico P; Viganò M; Colombo M
Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
[TBL] [Abstract][Full Text] [Related]
24. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
[TBL] [Abstract][Full Text] [Related]
25. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.
Zhang Q; Lapalus M; Asselah T; Laouénan C; Moucari R; Martinot-Peignoux M; Bieche I; Estrabaud E; De Muynck S; Boyer N; Bedossa P; Vidaud M; Marcellin P; Lada O
J Viral Hepat; 2014 Jul; 21(7):525-32. PubMed ID: 24118626
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
Ratnam D; Dev A; Nguyen T; Sundararajan V; Harley H; Cheng W; Lee A; Rusli F; Chen R; Bell S; Pianko S; Sievert W
J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789
[TBL] [Abstract][Full Text] [Related]
27. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
Ma H; Yang RF; Wei L
J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
[TBL] [Abstract][Full Text] [Related]
28. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
[TBL] [Abstract][Full Text] [Related]
29. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
30. The serum IL-23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B.
Yu C; Gong X; Yang Q; Lian J; Xu K; Ruan B; Li L
Liver Int; 2015 May; 35(5):1549-56. PubMed ID: 25312687
[TBL] [Abstract][Full Text] [Related]
31. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
[TBL] [Abstract][Full Text] [Related]
32. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.
Moucari R; Martinot-Peignoux M; Mackiewicz V; Boyer N; Ripault MP; Castelnau C; Leclere L; Dauvergne A; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
Antivir Ther; 2009; 14(8):1183-8. PubMed ID: 20032548
[TBL] [Abstract][Full Text] [Related]
33. Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.
Penna A; Laccabue D; Libri I; Giuberti T; Schivazappa S; Alfieri A; Mori C; Canetti D; Lampertico P; Viganò M; Colombo M; Loggi E; Missale G; Ferrari C
J Hepatol; 2012 Jun; 56(6):1239-46. PubMed ID: 22326467
[TBL] [Abstract][Full Text] [Related]
34. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
[TBL] [Abstract][Full Text] [Related]
35. Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).
Chan HL; Wong VW; Chim AM; Wong GL; Chan HY; Sung JJ
Antivir Ther; 2008; 13(4):555-62. PubMed ID: 18672534
[TBL] [Abstract][Full Text] [Related]
36. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
[TBL] [Abstract][Full Text] [Related]
37. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
38. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
[TBL] [Abstract][Full Text] [Related]
39. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
